Drug Information

Drug General Information
Drug ID
D05BMC
Former ID
DIB013064
Drug Name
GW-42004
Synonyms
CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals
Indication Lipid metabolism disorder [ICD10:E75-E78] Phase 2 [549419]
Company
GW Pharmaceuticals plc
Target and Pathway
Target(s) Cannabinoid receptor 2 Target Info Modulator
Cannabinoid receptor 1 Target Info Modulator
KEGG Pathway Neuroactive ligand-receptor interactionhsa04015:Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling eventsR-HSA-373076:Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
BDNF signaling pathway
GPCR downstream signaling
GPCRs, Other
References
Ref 549419Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036909)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.